TB and Diabetes Intersection of Two Diseases

Similar documents
Disclosures. TB and CoMorbidities Challenges and Opportunities. Burden of TB. Outline of the lecture. Target testing for TB Infection TB HIV 3/25/2012

DM and TB Double Burden. Anil Kapur

Overview Diabetes in the CNMI Tuberculosis in the CNMI Integrating g Diabetes Mellitus (DM) and Tuberculosis (TB) Programs

Global, National, Regional

Global, National, Regional

Helping TB patients quit smoking: the potential impact, WHO recommendations and country experience

The epidemiology of tuberculosis

Substance Abuse and Tuberculosis Springfield, IL April 27, 2011

Opt-Out HIV Testing in U.S. Tuberculosis Clinics: A Survey of Current Practice and Perceived Barriers

4/25/2012. The information on patterns of infection and disease can assist in: Assessing current and evolving trends in TB

Tuberculosis Epidemiology

The Scaling-up of TB/HIV Collaborative Activities in the Asia-Pacific

Tuberculosis Populations at Risk

The American Experience with TB Elimination

The Scaling-up of TB/HIV Collaborative Activities in the Asia-Pacific

Tuberculosis Intensive November 17 20, 2015 San Antonio, TX

Treating TB What Happened? All the Patients Have Challenging Co-Morbid Conditions Now!

TB Intensive San Antonio, Texas May 7-10, 2013

Treatment of Tuberculosis, 2017

511,000 (57% new cases) ~50,000 ~30,000

Sirturo: a new treatment against multidrug resistant tuberculosis

TB Nurse Case Management San Antonio, Texas July 18 20, 2012

THE Price of a Pandemic 2017

Principle of Tuberculosis Control. CHIANG Chen-Yuan MD, MPH, DrPhilos

Tuberculosis and Diabetes Dec. 10, 2009 Dean Schillinger, M.D. and Gisela Schecter, M.D., M.P.H. 1 of 18

Treatment of Tuberculosis

Recipients of development assistance for health

GBD2013 Tuberculosis estimates of mortality, incidence and prevalence

LATENT TUBERCULOSIS SCREENING AND TREATMENT:

Appendix 3 Sample size and cost of surveys

Controlling Vaccine Preventable Diseases in the US and Global Immunization Efforts

Treatment of Tuberculosis Therapeutic Drug Monitoring

Please evaluate this material by clicking here:

Annual Tuberculosis Report Oregon 2007

The WHO END-TB Strategy

Global TB control: Current status with particular attention to TB among women and children

ANNUAL TUBERCULOSIS REPORT OREGON Oregon Health Authority Public Health Division TB Program November 2012

The Burden of Heart Failure in the Asia Pacific. Eugenio B. Reyes, M.D. Associate Professor, University of the Philippines, College of Medicine

A Summary of Childhood Cancer Statistics in Australia,

Cotton Trade 02/03 03/04 04/05 05/06 06/07 07/08 08/09 09/10 10/11 11/12 12/13

Annex 2 A. Regional profile: West Africa

The Epidemiology of Tuberculosis in Minnesota,

LTBI: Who to Test & When to Treat

Epidemiology of chronic diseases in developing countries. Prof Isaac Quaye, UNAM SOM

Update on Progress and Challenges in Achieving Measles and Rubella Targets

Mycobacterial Infections: What the Primary Provider Should Know about Tuberculosis

The WHO Global Project on anti-tb drug resistance surveillance: background, objectives, achievements, challenges, next steps

The World Bank s Reproductive Health Action Plan

Moving Past the Basics of Tuberculosis Phoenix, Arizona May 8-10, 2012

Tobacco and Tuberculosis:

: uptake and impact of Xpert MTB/RIF

TB and Comorbidities Adriana Vasquez, MD April 12, 2018

INH Prophylaxis Therapy (IPT) should NOT be implemented for all HIV patients in the Asia Pacific

Enriched RWE study in the Nordics a case study

Supplement 2: Extracted studies

TB EPIDEMIOLOGY. Outline. Estimated Global TB Burden, TB epidemiology

EPIDEMIOLOGY OF TUBERCULOSIS AND the IMPACT ON CHILDREN

WHO Global Task Force on TB Impact Measurement An overview

Diabetes Knowledge and Self-Management among Tuberculosis Patients in Hawai i, 2013

Overview. Therapeutic Window. Does drug concentration matter? Treatment of Tuberculosis Therapeutic Drug Monitoring

Errors in Dx and Rx of TB

WCPT COUNTRY PROFILE December 2017 JAPAN

WHAT'S IN A NUMBER? TWO RECENT REPORTS ESTIMATING CHILDHOOD TB CASES.

Drug-resistant Tuberculosis

TB in Prisons and Jails Albuquerque, New Mexico November 28, 2012

Predictive Value of interferon-gamma release assays for incident active TB disease: A systematic review

COSTS OF DIABETES IN DEVELOPING COUNTRIES

Substance Abuse and Tuberculosis Springfield, IL April 27, 2011

Diabetes and Tuberculosis: A Practical Approach to Diagnosis and Treatment

Treatment of Tuberculosis

Launch of a supplement in Health Policy and Planning. Dr. Joy Lawn Mary Kinney Anne Pfitzer On behalf of the team

Diagnosis and Medical Management of TB Disease. Quratulian Annie Kizilbash, MD, MPH March 17, 2015

Global Polybutylene Terephthalate (PBT) Market Study ( )

TB & HIV CO-INFECTION IN CHILDREN. Reené Naidoo Paediatric Infectious Diseases Broadreach Healthcare 19 April 2012

Therapeutic Drug Monitoring for Improving TB Treatment Outcomes: A Concept for a Randomized Clinical Trial before Clinical Implementation

TB, BCG and other things. Chris Conlon Infectious Diseases Oxford

Management of MDR TB in special situations. Dr Sarabjit Chadha The Union

Treatment of Latent TB Infection (LTBI)

GOAL 2: ACHIEVE RUBELLA AND CRS ELIMINATION. (indicator G2.2) Highlights

TB In Detroit 2011* Early TB: Smudge Sign. Who is at risk for exposure to or infection with TB? Who is at risk for TB after exposure or infection?

The United Nations flag outside the Secretariat building of the United Nations, New York City, United States of America

Global Terephthalic Acid (PTA) Market Study ( )

DIAGNOSIS AND MEDICAL MANAGEMENT OF TB DISEASE

Substance Abuse and Tuberculosis Oklahoma City, Oklahoma November 17, 2010

Guidance for Identifying Risk Factors for Mycobacterium tuberculosis (MTB) During Evaluation of Potential Living Kidney Donors

Experiences on Workforce Development in Other Regions

GLOBAL TB IMPACT MEASUREMENT

The Global Picture in Blood Transfusions: A Quick Overview

Contact Investigation and Prevention in the USA

TB Intensive San Antonio, Texas November 11 14, 2014

Latent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016

Tuberculosis and Diabetes Mellitus. Lana Kay Tyer, RN MSN WA State Department of Health TB Nurse Consultant

Marcos Burgos, MD has the following disclosures to make:

TB 2015 burden, challenges, response. Dr Mario RAVIGLIONE Director

Child undernutrition based on the new WHO growth standards and rates of reduction to 2015

Tuberculosis and Diabetes

Evaluation and Management of the Patient with Latent Tuberculosis Infection (LTBI)

TB Intensive San Antonio, Texas

GLOBAL OUTLOOK ECONOMIC WATCH. March 2018

Transcription:

TB and Diabetes Intersection of Two Diseases E. Jane Carter, M.D. Associate Professor of Medicine Alpert School of Medicine at Brown University Providence, Rhode Island

Disclosures No financial disclosures Board Involvement World Lung Foundation International Union Against TB and Lung Disease Committee Involvement Advisory Committee for the Elimination of TB-CDC International Health Committee ATS Expert Committee - TB Active Case Finding -WHO

Questions to examine today: Does Diabetes contribute to the global burden of Tuberculosis? Does coexistence of TB and Diabetes in the same patient affect the course of the other clinical condition? Does treatment of TB in the Diabetic Patient differ than other TB? Do opportunities in synergy exist for health care systems not for the diseases?

Does Diabetes contribute to the global burden of Tuberculosis?

Burden of TB 9.4 million new cases of TB disease per year 2 million deaths 1 infection per second Leading cause of death in PLWHA Leading cause of death in women of child bearing years globally

Target testing for TB We screen populations At risk for exposure and resultant infection At risk for development of disease if infected HIV infection 100 fold Use of biologic agents 70 fold Medical conditions that influence ability to contain infection Diabetes 3 fold

Diabetes as a contributor to the global Top 10 in TB India China Indonesia Nigeria Bangladesh Pakistan Ethiopia Philippines South Africa DRC burden of TB Top 10 in Diabetes India China USA Indonesia Japan Pakistan Russia Brazil Italy Bangladesh

The preference is that the 2 populations are mutually exclusive Diabetes 250 million 6m new annually Tuberculosis 14 million 9.4m new annually

Situation in a low TB incidence country Diabetes Tuberculosis Population where Diabetes now acts as a multipler

Situation in a High TB incidence Country Diabetes TB Population where Diabetes now acts as a

Global Distribution of DM and TB Diabetes 2008 South East Asia 20% Western Pacific 23% Africa 5% Tuberculosis 2009 South East Asia 35% Western Pacific 20% Africa 30% 70% in LIC and MIC 95% in LIC and MIC By sheer numbers, Diabetes CoMorbidity may contribute As much or more to TB Incidence burden than HIV despite being a weaker inducer

Does coexistence of TB and Diabetes in the same patient affect the course of the other clinical condition?

Presentation of Disease Some studies have demonstrated more common atypical presentations Turkey Saudi Arabia Pakistan Taiwan Some studies have suggested more cavitation

Outcome of Disease Possible delay in Sputum Culture conversion 8 studies comparing DM and Non DM RR 0.8-3.2 but 5/8 had RR >2 Possible Increase Death 23 studies comparing risk of death Pooled RR =1.85 ( 95% confidence interval;1.5-2.3) Possible Risk of Recurrent Disease 4 studies Pooled RR=3.98 ( 95% CI, 2.1-7.5)

Why might Diabetics do Worse? Drug Drug interactions Rifampin reduces levels of oral hypoglycemic Diabetes is a risk factor for hepatotoxicity from TB drugs

Why might Diabetics do Worse? TB risk seems to correlate with duration and severity of diabetes More post primary TB Higher bacterial burden Worse Immunopathology High Cytokine levels Slow response to treatment Synergy with other Co-morbidities

Does treatment of TB in the Diabetic Patient differ than other TB?

Treatment Considerations Peripheral neuropathy DM versus TB meds Diabetics should always be given B6 for prevention Drug Interactions Rifampin Oral Hypoglycemics Malabsorption Diabetics have been shown ot be at risk for malabsorption of medications Length of Therapy

Risk of Relapse (Study22) Continuation phase, Control, (I/R 2x/wk) Cavity Culture positive at 2 months Yes 21.8% 6.2% Culture negative at 2 months No 5.0% 2.1%

Treatment Implications Diabetics have prolonged culture positivity Extend by 3 months Diabetics may have more cavitary disease Extend by 3 months Whether Diabetes itself should predict longer therapy is unclear??? If neither of the above risk factors are present

Do opportunities in synergy exist for health care systems not for the diseases?

Saipan Experience Diabetes recorded in the TB clinic data base Most common co-morbidity 30% of all cases Over 70% of Pacific Island Cases Development of Diabetes Protocols for the TB Clinic

DM Guidelines Every person with TB over age 18 should be screened for Diabetes All Pacific Islanders with DM who are at risk for TB should be screened for LTBI and active TB Diabetics with LTBI should be encouraged to take INH for 9 months Ensure that TB treatment is appropriately adjusted for Diabetes B6 supplementation; Kidney function assessment ( Cr)

Ensure that TB treatment is appropriately adjusted for Diabetes B6 supplementation Kidney function assessment ( Cr) Be aware of drug interactions Be aware of poor absorption of some TB medications Be aware of the possibility of relapse in treatment not extended Repeat glucose monitoring during the course of treatment Appointments and DOT visits can be used as DM Teachable Moments

Universal TB Screening of all Diabetics? Remember- you do have to have TB infection for Diabetes to increase the risk of disease Targeted Testing In Diabetic Services who deliver care to TB risk populations All (TB) Epi is Local. Certainly represents an Opportunity for Synergy

The preference is that the 2 populations are mutually exclusive Diabetes 250 million 6m new annually Tuberculosis 14 million 9.4m new annually

Situation in a low TB incidence area Diabetes Tuberculosis Population where Diabetes now acts as a multipler

Situation in a High TB incidence Area Diabetes TB Population where Diabetes now acts as a

Summary Diabetes has been an ignored contributor to the overall TB global burden. With increasing incidence of diabetes in areas of high incidence TB, this will be a growing problem. There is no evidence to date that diabetics are at increased risk of infection if exposed. Diabetes increases the risk of progression to disease by at least 3 fold.

Summary Diabetes may influence Co-morbidities and their influence on TB may offer opportunities for synergistic care programs

Stop TB. Thank you for your attention. Questions?